DK2395840T3 - Farmaceutiske formuleringer af nitazoxanid med kontrolleret frigivelse - Google Patents

Farmaceutiske formuleringer af nitazoxanid med kontrolleret frigivelse Download PDF

Info

Publication number: DK2395840T3
Authority: DK; Denmark
Prior art keywords: nitazoxanide; controlled release; pharmaceutical formulations; formulations; pharmaceutical
Prior art date: 2009-02-13

Application number

DK10741758.6T

Other languages

English (en)

Inventor

Marc Ayers

Jean-Francois Rossignol

Original Assignee

Romark Laboratories Lc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-13

Filing date

2010-02-12

Publication date

2020-06-08

2010-02-12 Application filed by Romark Laboratories Lc filed Critical Romark Laboratories Lc

2020-06-08 Application granted granted Critical

2020-06-08 Publication of DK2395840T3 publication Critical patent/DK2395840T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

DK10741758.6T 2009-02-13 2010-02-12 Farmaceutiske formuleringer af nitazoxanid med kontrolleret frigivelse DK2395840T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20228509P	2009-02-13	2009-02-13
PCT/US2010/024000 WO2010093854A1 (en)	2009-02-13	2010-02-12	Controlled release pharmaceutical formulations of nitazoxanide

Publications (1)

Publication Number	Publication Date
DK2395840T3 true DK2395840T3 (da)	2020-06-08

Family

ID=42560126

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK10741758.6T DK2395840T3 (da)	2009-02-13	2010-02-12	Farmaceutiske formuleringer af nitazoxanid med kontrolleret frigivelse

Country Status (23)

Country	Link
US (5)	US8524278B2 (da)
EP (1)	EP2395840B1 (da)
JP (3)	JP5726766B2 (da)
KR (1)	KR101697800B1 (da)
CN (2)	CN107260695A (da)
AU (3)	AU2010213678B2 (da)
BR (1)	BRPI1007945C8 (da)
CA (1)	CA2752233C (da)
CO (1)	CO6501159A2 (da)
CY (1)	CY1123162T1 (da)
DK (1)	DK2395840T3 (da)
EA (1)	EA029018B1 (da)
ES (1)	ES2797493T3 (da)
HR (1)	HRP20201055T1 (da)
HU (1)	HUE049501T2 (da)
IL (1)	IL214624A0 (da)
LT (1)	LT2395840T (da)
MX (2)	MX348282B (da)
PL (1)	PL2395840T3 (da)
PT (1)	PT2395840T (da)
SI (1)	SI2395840T1 (da)
UA (1)	UA107564C2 (da)
WO (1)	WO2010093854A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2636527C (en) *	2006-01-09	2016-05-17	Romark Laboratories, L.C.	Viral hepatitis treatment
KR101697800B1 (ko)	2009-02-13	2017-01-18	로마크 레버러토리즈, 엘.씨.	니타족사니드의 서방성 제약 제형
MX340846B (es)	2012-01-27	2016-07-28	Rhein Siegfried Sa De Cv	Composición de nitazoxanida mejorada y proceso para prepararla.
US20150017242A1 (en) *	2012-02-20	2015-01-15	Lupin Limited	Bilayer Tablet of Dronedarone
KR101639692B1 (ko) *	2013-12-13	2016-07-14	제일약품주식회사	2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
BR112017009651A2 (pt)	2014-11-11	2017-12-19	Romark Laboratories Lc	composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.
PT3436074T (pt)	2016-03-31	2020-08-21	Romark Laboratories Lc	Compostos tiazolida para tratamento de infeções virais
KR102410951B1 (ko) *	2016-04-11	2022-06-20	장피트	담즙정체성 및 섬유증 질환의 치료 방법
US10905680B2 (en) *	2016-04-11	2021-02-02	Genfit	Methods of treatment for cholestatic and fibrotic diseases
ES2958616T3 (es) *	2017-03-08	2024-02-12	Cinrx Pharma Llc	Formulaciones farmacéuticas de floroglucinol y trimetilfloroglucinol
CA3054103A1 (en) *	2017-03-13	2018-09-20	Genfit	Pharmaceutical compositions for combination therapy
US11173149B2 (en)	2017-04-18	2021-11-16	Romark Laboratories L.C.	Inhibition of protein disulfide-isomerase A3
EP3639854A4 (en)	2017-06-16	2021-03-03	The Doshisha	MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF
US20200121652A1 (en) *	2017-06-16	2020-04-23	The Doshisha	Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
CN108524460B (zh) *	2018-05-14	2021-01-01	佛山市南海东方澳龙制药有限公司	烯啶虫胺双层片
WO2019241376A1 (en)	2018-06-14	2019-12-19	The Trustees Of Columbia University In The City Of New York	Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
CN110025621A (zh) *	2019-03-13	2019-07-19	中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心)	替唑尼特和硝唑尼特在制备抗炎药物中的应用
CN111012788B (zh) *	2019-12-12	2021-01-15	武汉职业技术学院	硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
WO2021125824A1 (ko) *	2019-12-19	2021-06-24	(주)셀트리온	시벤졸린 또는 이의 염을 포함하는 약학 제형
EP4182304A1 (en)	2020-07-20	2023-05-24	Romark Laboratories, L.C.	Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
JP2023538136A (ja)	2020-08-24	2023-09-06	ロマークラボラトリーズ，リミティドカンパニー	コロナウイルスに対するチアゾリドの利用
WO2022130406A1 (en) *	2020-12-15	2022-06-23	Cipla Limited	Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease
DE112022004799T5 (de)	2021-10-05	2024-08-14	Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860)	Verbessertes Verfahren zur Herstellung von Nitazoxanid und Zwischenprodukten davon
CN114259492A (zh) *	2021-12-21	2022-04-01	中以海德人工智能药物研发股份有限公司	硝唑尼特在治疗乙肝中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1437800A (en)	1973-08-08	1976-06-03	Phavic Sprl	Derivatives of 2-benzamido-5-nitro-thiazoles
JPH06316517A (ja) *	1993-02-22	1994-11-15	Grelan Pharmaceut Co Ltd	放出制御製剤
US5387598A (en) *	1994-04-13	1995-02-07	Rossignol; Jean-Francois	Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) *	1994-09-08	1996-11-26	Romark Lab Lc	Benzamide derivatives
US5968961A (en) *	1997-05-07	1999-10-19	Romark Laboratories, L.C.	Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) *	1994-09-08	1998-02-28	Jean-Francois Rossignol	Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
AU740022B2 (en) *	1997-05-07	2001-10-25	Romark Laboratories, L.C.	Pharmaceutical compositions of tizoxanide and nitazoxanide
US5948440A (en)	1997-12-17	1999-09-07	Ranbaxy Laboratories Limited	Modified release matrix formulation of cefaclor and cephalexin
HU230454B1 (hu)	1998-11-02	2016-07-28	Alkermes Pharma Ireland Limited	Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
GB0009522D0 (en) *	2000-04-19	2000-06-07	Smithkline Beecham Plc	Composition
DE10031043A1 (de) *	2000-06-26	2002-02-14	Bayer Ag	Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
JP4637338B2 (ja) *	2000-09-22	2011-02-23	大塚製薬株式会社	シロスタゾール有核錠
CA2426666A1 (en)	2000-09-29	2002-04-04	Solvay Pharmaceuticals B.V.	Ion-strength independent sustained release pharmaceutical formulation
US7074417B2 (en)	2000-10-13	2006-07-11	Advancis Pharmaceutical Corporation	Multiple-delayed release anti-viral product, use and formulation thereof
CN100408029C (zh) *	2001-09-28	2008-08-06	麦克内尔-Ppc股份有限公司	有镶嵌部分的组合剂型
EP1435931A2 (en)	2001-09-28	2004-07-14	Sun Pharmaceuticals Industries Ltd.	Dosage form for treatment of diabetes mellitus
US7985422B2 (en) *	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
UY28457A1 (es)	2003-08-07	2005-03-31	Sb Pharmco Inc	Nueva composición
GB0319874D0 (en) *	2003-08-22	2003-09-24	Glaxo Group Ltd	Novel formulation
UA90864C2 (en) *	2004-09-09	2010-06-10	Ромарк Лебораториз, Л.К.	Halogenated benzamide derivatives
WO2006070406A1 (en) *	2004-12-29	2006-07-06	J.B. Chemicals & Pharmaceuticals Ltd	Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
EP2047850A3 (en) *	2005-04-12	2009-07-29	Romark Laboratories, L.C.	Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
FR2889811B1 (fr)	2005-08-19	2009-10-09	Sanofi Aventis Sa	Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
CA2636527C (en) *	2006-01-09	2016-05-17	Romark Laboratories, L.C.	Viral hepatitis treatment
JP2006335771A (ja) *	2006-09-22	2006-12-14	Takeda Chem Ind Ltd	徐放性製剤およびその製造方法
US20080299188A1 (en) *	2007-05-14	2008-12-04	Pfizer Inc.	Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US20080286344A1 (en) *	2007-05-16	2008-11-20	Olivia Darmuzey	Solid form
BRPI0815057B8 (pt)	2007-08-03	2021-05-25	Romark Laboratories Lc	composto, composição farmacêutica, e, uso de um composto
KR101697800B1 (ko) *	2009-02-13	2017-01-18	로마크 레버러토리즈, 엘.씨.	니타족사니드의 서방성 제약 제형

2010
- 2010-02-12 KR KR1020117020973A patent/KR101697800B1/ko not_active Expired - Fee Related
- 2010-02-12 LT LTEP10741758.6T patent/LT2395840T/lt unknown
- 2010-02-12 BR BRPI1007945A patent/BRPI1007945C8/pt not_active IP Right Cessation
- 2010-02-12 CN CN201710263825.6A patent/CN107260695A/zh active Pending
- 2010-02-12 US US12/656,704 patent/US8524278B2/en not_active Expired - Fee Related
- 2010-02-12 JP JP2011550246A patent/JP5726766B2/ja active Active
- 2010-02-12 PL PL10741758T patent/PL2395840T3/pl unknown
- 2010-02-12 CA CA2752233A patent/CA2752233C/en not_active Expired - Fee Related
- 2010-02-12 EP EP10741758.6A patent/EP2395840B1/en active Active
- 2010-02-12 MX MX2011008530A patent/MX348282B/es active IP Right Grant
- 2010-02-12 DK DK10741758.6T patent/DK2395840T3/da active
- 2010-02-12 HU HUE10741758A patent/HUE049501T2/hu unknown
- 2010-02-12 SI SI201032014T patent/SI2395840T1/sl unknown
- 2010-02-12 ES ES10741758T patent/ES2797493T3/es active Active
- 2010-02-12 EA EA201190127A patent/EA029018B1/ru not_active IP Right Cessation
- 2010-02-12 MX MX2017006915A patent/MX381895B/es unknown
- 2010-02-12 HR HRP20201055TT patent/HRP20201055T1/hr unknown
- 2010-02-12 CN CN2010800164251A patent/CN102395276A/zh active Pending
- 2010-02-12 PT PT107417586T patent/PT2395840T/pt unknown
- 2010-02-12 AU AU2010213678A patent/AU2010213678B2/en not_active Ceased
- 2010-02-12 WO PCT/US2010/024000 patent/WO2010093854A1/en not_active Ceased
- 2010-12-02 UA UAA201110567A patent/UA107564C2/uk unknown
2011
- 2011-08-11 IL IL214624A patent/IL214624A0/en active IP Right Grant
- 2011-09-07 CO CO11115308A patent/CO6501159A2/es not_active Application Discontinuation
2013
- 2013-07-30 US US13/954,184 patent/US9351937B2/en not_active Expired - Fee Related
2015
- 2015-04-01 JP JP2015075264A patent/JP6117845B2/ja not_active Expired - Fee Related
2016
- 2016-02-16 AU AU2016200971A patent/AU2016200971B2/en not_active Ceased
- 2016-04-29 US US15/141,921 patent/US9827227B2/en active Active - Reinstated
- 2016-12-09 JP JP2016239374A patent/JP6491174B2/ja not_active Expired - Fee Related
2017
- 2017-05-11 AU AU2017203148A patent/AU2017203148B2/en not_active Ceased
- 2017-11-16 US US15/814,850 patent/US10383855B2/en active Active
2019
- 2019-07-02 US US16/460,161 patent/US11426388B2/en active Active
2020
- 2020-07-07 CY CY20201100626T patent/CY1123162T1/el unknown

Also Published As

Publication number	Publication date
EP2395840A4 (en)	2013-12-25
WO2010093854A1 (en)	2010-08-19
BRPI1007945B8 (pt)	2020-08-18
KR20120008024A (ko)	2012-01-25
AU2016200971B2 (en)	2017-02-23
IL214624A0 (en)	2011-09-27
JP6491174B2 (ja)	2019-03-27
BRPI1007945C1 (pt)	2020-09-01
JP2012518002A (ja)	2012-08-09
US10383855B2 (en)	2019-08-20
PL2395840T3 (pl)	2020-09-07
AU2010213678B2 (en)	2015-11-26
AU2010213678A1 (en)	2011-09-01
EP2395840A1 (en)	2011-12-21
JP6117845B2 (ja)	2017-04-19
JP2017061561A (ja)	2017-03-30
US20100209505A1 (en)	2010-08-19
CA2752233C (en)	2017-01-03
US20190321338A1 (en)	2019-10-24
MX381895B (es)	2025-03-13
AU2016200971A1 (en)	2016-03-03
MX2011008530A (es)	2011-10-14
EA201190127A1 (ru)	2012-03-30
JP2015143258A (ja)	2015-08-06
LT2395840T (lt)	2020-07-10
BRPI1007945C8 (pt)	2021-05-25
CN107260695A (zh)	2017-10-20
ES2797493T3 (es)	2020-12-02
BRPI1007945A2 (pt)	2015-09-01
EP2395840B1 (en)	2020-04-15
CY1123162T1 (el)	2021-10-29
US9827227B2 (en)	2017-11-28
US20160243087A1 (en)	2016-08-25
US11426388B2 (en)	2022-08-30
AU2017203148A1 (en)	2017-06-01
UA107564C2 (uk)	2015-01-26
US8524278B2 (en)	2013-09-03
AU2017203148B2 (en)	2018-08-09
BRPI1007945B1 (pt)	2020-08-04
CN102395276A (zh)	2012-03-28
HRP20201055T1 (hr)	2020-10-30
MX348282B (es)	2017-06-05
CA2752233A1 (en)	2010-08-19
HUE049501T2 (hu)	2020-09-28
US20180085353A1 (en)	2018-03-29
KR101697800B1 (ko)	2017-01-18
US9351937B2 (en)	2016-05-31
SI2395840T1 (sl)	2020-08-31
CO6501159A2 (es)	2012-08-15
EA029018B1 (ru)	2018-01-31
US20140065215A1 (en)	2014-03-06
PT2395840T (pt)	2020-07-06
JP5726766B2 (ja)	2015-06-03

Publication	Publication Date	Title
DK2395840T3 (da)	2020-06-08	Farmaceutiske formuleringer af nitazoxanid med kontrolleret frigivelse
DK2498756T3 (da)	2019-11-25	Tabletformuleringer af neratinibmaleat
PT2435030E (pt)	2015-02-27	Composições farmacêuticas flutuantes de libertação controlada
DK3061445T3 (da)	2023-09-11	Højkoncentrerede farmaceutiske formuleringer
BR112012011733A2 (pt)	2019-09-24	formulações de comprimido de liberação imediata
DK2787975T3 (da)	2017-11-20	Robuste formuleringer med kontrolleret frigivelse
HRP20181347T1 (hr)	2018-10-19	Formulacije dvoslojne tablete
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
IL217153A0 (en)	2012-02-29	Controlled release formulations
DK2714004T3 (da)	2024-06-10	Peptidformuleringer med kontrolleret frigivelse
DK2452281T3 (da)	2020-01-13	Fremgangsmåde til at forudsige virkningen af lægemidler i en patient
BRPI1012539A2 (pt)	2016-03-29	composições farmacêuticas
DK2462116T3 (da)	2014-10-13	Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser
SMT201400069B (it)	2014-07-07	Formulazione farmaceutica
BRPI1015939A2 (pt)	2016-09-27	composição farmacêutica
GT201200303A (es)	2014-04-29	Formulaciones farmacéuticas
IT1394400B1 (it)	2012-06-15	Composizioni farmaceutiche
DK2391351T3 (da)	2014-12-01	Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
BRPI0912428A2 (pt)	2016-02-16	formulação farmacêutica sólida de liberação retardada
BRPI0922653A2 (pt)	2016-01-05	preparação farmacêutica
EP2554168A4 (en)	2015-05-20	PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE
HUE054030T2 (hu)	2021-08-30	Fejlesztett formulációk
BR112012003149A2 (pt)	2016-03-01	composição farmacêutica
DK2462108T3 (da)	2013-07-08	Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider